The financial costs of healthcare treatment for people with Type 1 or Type 2 diabetes in the UK with particular reference to differing severity of peripheral neuropathy

Currie, CJ; Poole, Chris; Woehl, Anette; Morgan, Christopher L.; Cawley, Scott; Rousculp, Matthew D.; Covington, M.; Peters, John R.

doi:10.1111/j.1464-5491.2006.02057.x

Cited by 49 publications

(22 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 19 The estimate of the current, annual cost of monitoring, prescribing and treating microvascular complications amounts to about £2,300 per patient. This is broadly consistent with a recent estimate of the total healthcare cost of treating people with type 1 diabetes in the UK by Currie et al [75]. The annual healthcare cost of participants in their survey spent about £3,200 a year, including treatment and prevention of macrovascular complications such as stroke and myocardial infarction.…”

Section: Diabetic Footsupporting

confidence: 89%

Requisite models for strategic commissioning: the example of type 1 diabetes

Airoldi¹,

Bevan²,

Morton³

et al. 2008

Health Care Manage Sci

View full text Add to dashboard Cite

A developing emphasis of health care reforms has been creating organisations with responsibilities for strategic commissioning of services for defined populations. Such organisations must set priorities in aiming to meet their populations' needs subject to a budget constraint. This requires estimates of the health benefits and costs of different interventions for their populations. This paper outlines a framework that does this and shows how this requires modelling to produce estimates in a way that is transparent to commissioners, of requisite complexity to produce sound estimates for priority setting using routinely available data. The example illustrated in this paper is an intervention that would improve glucose control in the English population with type 1 diabetes. It takes many years for a change in glucose management to deliver maximum benefits; hence the intervention is not good value-for-money in the short run. We aim to give a more strategic view of the costs and benefits modelling costs and benefits in a steady-state model which suggests that the intervention is good value-for-money in the long run.

show abstract

Section: Diabetic Footsupporting

confidence: 89%

Requisite models for strategic commissioning: the example of type 1 diabetes

Airoldi¹,

Bevan²,

Morton³

et al. 2008

Health Care Manage Sci

View full text Add to dashboard Cite

show abstract

“…Health-related QOL has been described in several studies in diabetes neuropathy showing lower healthrelated QOL in patients with diabetes than in our group of patients with cryptogenic polyneuropathy [6][7][8].…”

Section: Discussionmentioning

confidence: 95%

“…As cryptogenic polyneuropathy is typically present in the elderly, and the number of people affected is expected to increase in view of a growing aging population, it is important to know the impact of disease on QOL. During the last years, several studies of health-related QOL in patients with different kinds of neuropathies have been done, especially in diabetic neuropathy [6][7][8], but also in other neuropathies [9][10][11][12][13][14][15][16][17][18][19]. However, the knowledge about QOL in patients with cryptogenic polyneuropathy is still limited and is often regarded as slowly progressive without major impacts on daily living [20].…”

Section: Introductionmentioning

confidence: 99%

Health-related quality of life in patients with cryptogenic polyneuropathy compared with the general population

Lindh¹,

Tondel²,

Persson³

et al. 2010

Disability and Rehabilitation

View full text Add to dashboard Cite

show abstract

“…However, as the disease progresses complications are likely to set in and result in a gradual decrease over time in HRQoL among individuals with diabetes beyond that of the general population. Several studies have shown that long-term complications of diabetes such as ischemic heart disease, stroke, neuropathy and retinopathy have a negative impact on HRQoL [9,23-27]. …”

Section: Introductionmentioning

confidence: 99%

Diabetes duration and health-related quality of life in individuals with onset of diabetes in the age group 15—34 years – a Swedish population-based study using EQ-5D

et al. 2013

View full text Add to dashboard Cite

BackgroundDiabetes with onset in younger ages affects both length of life and health status due to debilitating and life-threatening long-term complications. In addition, episodes and fear of hypoglycaemia and of long-term consequences may have a substantial impact on health status. This study aims to describe and analyse health-related quality of life (HRQoL) in individuals with onset of diabetes at the age of 15—34 years and with a disease duration of 1, 8, 15 and 24 years compared with control individuals matched for age, sex and county of residence.MethodsCross-sectional study of 839 individuals with diabetes and 1564 control individuals. Data on socioeconomic status and HRQoL using EQ-5D were collected by a postal questionnaire. Insulin treatment was self-reported by 94% of the patients, the majority most likely being type 1.ResultsIndividuals with diabetes reported lower HRQoL, with a significantly lower mean EQ VAS score in all cohorts of disease duration compared with control individuals for both men and women, and with a significantly lower EQ-5Dindex for women, but not for men, 15 years (0.76, p = 0.022) and 24 years (0.77, p = 0.016) after diagnosis compared with corresponding control individuals. Newly diagnosed individuals with diabetes reported significantly more problems compared with the control individuals in the dimension usual activities (women: 13.2% vs. 4.0%, p = 0.048; men: 11.4% vs. 4.1%, p = 0.033). In the other dimensions, differences between individuals with diabetes and control individuals were found 15 and 24 years after diagnosis: for women in the dimensions mobility, self-care, usual activities and pain/discomfort and for men in the dimension mobility. Multivariable regression analysis showed that diabetes duration, being a woman, having a lower education and not being married or cohabiting had a negative impact on HRQoL.ConclusionsOur study confirms the negative impact of diabetes on HRQoL and that the difference to control individuals increased by disease duration for women with diabetes. The small difference one year after diagnosis could imply a good management of diabetes care and a relatively quick adaptation. Our results also indicate that gender differences still exist in Sweden, despite modern diabetes treatment and management in Sweden.

show abstract

The financial costs of healthcare treatment for people with Type 1 or Type 2 diabetes in the UK with particular reference to differing severity of peripheral neuropathy

Abstract: This study demonstrated that severity of DPN symptoms was associated with increased healthcare resource use, thus costs.

Cited by 49 publications

References 14 publications

Requisite models for strategic commissioning: the example of type 1 diabetes

Requisite models for strategic commissioning: the example of type 1 diabetes

Health-related quality of life in patients with cryptogenic polyneuropathy compared with the general population

Diabetes duration and health-related quality of life in individuals with onset of diabetes in the age group 15—34 years – a Swedish population-based study using EQ-5D

Contact Info

Product

Resources

About